Skip to main content
. 2017 May 2;8(28):46145–46162. doi: 10.18632/oncotarget.17574

Figure 1. The anticancer effect of IFNγ on cervical cancer.

Figure 1

(A) HeLa and SiHa cells were treated with the indicated doses of IFNγ for 72 h, and then cell viability was examined by MTT assay. A p value of < 0.01 (**) or < 0.001(***) indicates significant differences between IFNγ-treated and control cells. (B) The microarray data of IFNγ-treated HeLa cells were analyzed by GSEA. The most upregulated and downregulated genes were illustrated on a heat map. Top-50 genes upregulated and downregulated by IFNγ were further analyzed by the FunRich software for pathway enrichment. Pathways were ranked according to the p value (red bar). A p value lower than 0.05 (yellow bar) was considered significant. The blue bar indicated the percentage of altered genes in a whole pathway. (C) HeLa cells were treated with 100 ng/mL IFNγ for 24, 48, and 72 h, and then cell cycle distribution was examined by flow cytometry.